GlassScriptPhysician profile
Anna Hien Tran
NPI 1104423250
$6,479.95
in general payments reported to CMS, 2019-2025
24 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,917 · 2022: $1,498 · 2023: $1,831 · 2024: $115 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.20 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,183.71 | 2021-2023 | Austedo Xr, Austedo |
| Alkermes, INC. | $850.51 | 2021-2023 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $612.33 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $539.05 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $475.63 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $455.23 | 2021-2023 | Nuplazid |
| Abbvie INC. | $414.56 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $360.15 | 2022-2023 | Quviviq |
| Sun Pharmaceutical Industries INC. | $287.45 | 2021 | |
| Axsome Therapeutics, INC. | $179.49 | 2023 | Auvelity, Sunosi |
| Bioxcel Therapeutics, INC. | $161.11 | 2023 | Igalmi |
| Indivior INC. | $154.66 | 2021-2023 | Perseris |
| Bausch Health US, LLC | $146.28 | 2021 | |
| Jazz Pharmaceuticals INC. | $140.02 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $119.21 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $101.03 | 2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $80.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.11 | 2021-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $55.79 | 2021 | |
| Neos Therapeutics, LP | $39.25 | 2022 | |
| Harmony Biosciences LLC | $20.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.53 | 2024 | Qelbree |
| Eisai INC. | $13.31 | 2021 | |
| Noven Therapeutics, LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.